NCT06610643

Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: National Taiwan University Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the safety and efficacy of extended remdesivir infusion, targeting on immunocompromised individuals who had positive SARS-CoV-2 PCR despite an oral antiviral agent prescription.

Detailed description

Prolonged viral shedding is commonly observed in immunocompromised patients infected by SARS-CoV-2. Until now, there is no successful clinical trial or guideline to guide optimal treatment for this clinical condition. Here, we aimed to establish a clinical trial with combination of prolonged remdesivir infusion with nirmatrelvir/ritonavir among COVID-19 patients recently receiving b-cell depletion therapy, to evaluate to clinical outcomes.

Conditions

• COVID-19
• SARS-CoV-2
• Immunocompromised

Interventions

Type	Name	Description
DRUG	combination therapy	A combination of 5-day remdesivir and 10-day Nirmatrelvir/Ritonavir
DRUG	SOC	Standard of care

Timeline

• Start date: 2024-09-21
• Primary completion: 2026-09-30
• Completion: 2026-12-31
• First posted: 2024-09-24
• Last updated: 2024-09-25

Locations

1 site across 1 country: Taiwan